Abstract:ABSTRACTChemokines and their receptors play important roles in normal physiological functions and the pathogeneses of a wide range of human diseases, including the entry of human immunodeficiency virus type 1 (HIV-1). However, the use of natural chemokines to probe receptor biology or to develop therapeutic drugs is limited by their lack of selectivity and the poor understanding of mechanisms in ligand-receptor recognition. We addressed these issues by combining chemical and structural biology in research into molecular recognition and inhibitor design. Specifically, the concepts of chemical biology were used to develop synthetically and modularly modified (SMM) chemokines that are unnatural and yet have properties improved over those of natural chemokines in terms of receptor selectivity, affinity, and the ability to explore receptor functions. This was followed by using structural biology to determine the structural basis for synthetically perturbed ligand-receptor selectivity. As a proof-of-principle for this combined chemical and structural-biology approach, we report a noveld-amino acid-containing SMM-chemokine designed based on the natural chemokine called viral macrophage inflammatory protein II (vMIP-II). The incorporation of unnaturald-amino acids enhanced the affinity of this molecule for CXCR4 but significantly diminished that for CCR5 or CCR2, thus yielding much more selective recognition of CXCR4 than wild-type vMIP-II. Thisd-amino acid-containing chemokine also showed more potent and specific inhibitory activity against HIV-1 entry via CXCR4 than natural chemokines. Furthermore, the high-resolution crystal structure of thisd-amino acid-containing chemokine and a molecular-modeling study of its complex with CXCR4 provided the structure-based mechanism for the selective interaction between the ligand and chemokine receptors and the potent anti-HIV activity ofd-amino acid-containing chemokines.

Structure-Based Design of 1-Heteroaryl-1,3-propanediamine Derivatives As a Novel Series of CC-Chemokine Receptor 5 Antagonists.

Design, Synthesis, and Biological Activity of Novel Octahydro-1H-pyrrolo[3,2-c]pyridine Derivatives As C-C Chemokine Receptor Type 5 (CCR5) Antagonists

Design, Synthesis, and Biological Evaluation of Novel Piperidine-4-carboxamide Derivatives As Potent CCR5 Inhibitors

Design, Synthesis, and Biological Evaluation of Novel 2-Methylpiperazine Derivatives As Potent CCR5 Antagonists.

Discovery of a Novel CCR5 Antagonist Lead Compound Through Fragment Assembly

Design, Synthesis and Biological Evaluation of Novel Piperazine Derivatives As CCR5 Antagonists

Design, Synthesis, and Structure-Activity-relationship of a Novel Series of CXCR4 Antagonists.

Recent Progress in Small Molecule CCR5 Antagonists As Potential HIV-1 Entry Inhibitors

Medicinal chemistry of small molecule CCR5 antagonists for blocking HIV-1 entry: a review of structural evolution.

Design, Synthesis, and Biological Characterization of a New Class of Symmetrical Polyamine-Based Small Molecule CXCR4 Antagonists.

Design, Synthesis and Biological Activity of Bicyclic Piperidine-Based HIV-1 Inhibitors

Molecular binding mode of PF-232798, a clinical anti-HIV candidate, at chemokine receptor CCR5

Efficient Synthesis and Identification of Novel Propane-1,3-diamino Bridged CCR5 Antagonists with Variation on the Basic Center Carrier

Advances of CCR5 antagonists: From small molecules to macromolecules

Structure-Based Design of Tropane Derivatives as a Novel Series of CCR5 Antagonists with Broad-Spectrum Anti-HIV-1 Activities and Improved Oral Bioavailability

Identification of Potential CCR5 Inhibitors Through Pharmacophore-Based Virtual Screening, Molecular Dynamics Simulation and Binding Free Energy Analysis

Structure of the CCR5 Chemokine Receptor–HIV Entry Inhibitor Maraviroc Complex

The Research of Anti-HIV Drugs Small Molecular CCR5 Antagonist

Chemokine Receptor CCR5 Antagonist Maraviroc: Medicinal Chemistry and Clinical Applications.

Crystal Structure and Structural Mechanism of a Novel Anti-Human Immunodeficiency Virus Andd-Amino Acid-Containing Chemokine

Discovery of Novel 1,4-Disubstituted 1,2,3-Triazole Phenylalanine Derivatives As HIV-1 Capsid Inhibitors